"Remission Induction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic act or process that initiates a response to a complete or partial remission level.
| Descriptor ID |
D012074
|
| MeSH Number(s) |
E02.860
|
| Concept/Terms |
Remission Induction- Remission Induction
- Induction, Remission
- Inductions, Remission
- Induction of Remission
- Remission Inductions
|
Below are MeSH descriptors whose meaning is more general than "Remission Induction".
Below are MeSH descriptors whose meaning is more specific than "Remission Induction".
This graph shows the total number of publications written about "Remission Induction" by people in this website by year, and whether "Remission Induction" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 6 | 6 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 4 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 6 | 6 |
| 2009 | 0 | 7 | 7 |
| 2010 | 0 | 7 | 7 |
| 2011 | 0 | 7 | 7 |
| 2012 | 2 | 1 | 3 |
| 2013 | 0 | 12 | 12 |
| 2014 | 0 | 7 | 7 |
| 2015 | 0 | 8 | 8 |
| 2016 | 0 | 9 | 9 |
| 2017 | 1 | 10 | 11 |
| 2018 | 0 | 9 | 9 |
| 2019 | 0 | 13 | 13 |
| 2020 | 0 | 12 | 12 |
| 2021 | 1 | 7 | 8 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 5 | 5 |
| 2024 | 0 | 7 | 7 |
| 2025 | 0 | 5 | 5 |
| 2026 | 0 | 9 | 9 |
To return to the timeline,
click here.
Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study. Am J Hematol. 2026 Sep; 101 Suppl 3:42-49.
-
Long-term remission and monocyclic course in Still's disease patients starting canakinumab early: data from the international AIDA network registry. Semin Arthritis Rheum. 2026 Oct; 80:153030.
-
Contemporary Management of Acute Heart Failure: From Emergency Presentation to Long-Term Remission. J Am Coll Cardiol. 2026 Jun 30; 87(25):3632-3650.
-
Cardiometabolic Outcomes after Surgical Remission of Endogenous Hypercortisolism: A Prospective Cohort Study. J Clin Endocrinol Metab. 2026 May 19; 111(6):1613-1627.
-
Effectiveness and persistence of biological and targeted synthetic treatment in patients with rheumatoid arthritis and chronic kidney disease: a multicentre, prospective cohort study. Lancet Rheumatol. 2026 Jul; 8(7):e550-e562.
-
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee. Bone Marrow Transplant. 2026 May; 61(5):591-600.
-
Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study. Inflamm Bowel Dis. 2026 Apr 01; 32(4):702-710.
-
Long-Term Outcomes in Seronegative Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2026 Aug; 78(8):998-1005.
-
Evaluation of ravulizumab trough levels in pediatric complement-mediated hemolytic uremic syndrome in remission. Pediatr Nephrol. 2026 Jun; 41(6):1753-1760.
-
TNF antagonists withdrawal is not advised in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis of randomized controlled trials. Int J Colorectal Dis. 2025 Dec 02; 40(1):245.